Latest Period
Q1 2026
Security Snapshot
FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share (FATE) Institutional Ownership
CUSIP: 31189P102
13F Institutional Holders and Ownership History from Q1 2014 to Q1 2026
Institutions Reporting
154
Shares (Excl. Options)
74,091,253
Price
$1.20
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Symbol
- FATE on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 74,091,253
- Total 13F value
- $88,865,631
- Portfolio coverage rank
- 0%
- Share change
- +1,886,722
- Value change
- +$3,266,686
- Number of holders
- 154
- Shares outstanding
- 122,342,805
- SEC-reported price per share
- $2.29
- Insider filing price
- $2.29
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- FATE - FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share is tracked under CUSIP 31189P102.
- 154 institutions reported positions in Q1 2026.
- 4 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 145 to 154 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $70,931,982 to $88,865,631.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 154 institutions filings for Q1 2026.
Security key
31189P102
Latest holder period
Q1 2026
13F holders
154
13D/G owners
4
CIK / CUSIP context first
Open Q1 2026 holders
FATE full holder history
FATE THERAPEUTICS INC SEC filings
FATE THERAPEUTICS INC company facts
FATE THERAPEUTICS INC insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 31189P102:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
4
Security
FATE
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Redmile Group, LLC | 15% | 0% | $21,874,894 | +$344,999 | 18,229,078 | +1.6% | Redmile Group, LLC | 20 Apr 2026 |
| BlackRock, Inc. | 6.9% | $10,600,447 | 7,852,183 | BlackRock, Inc. | 31 Mar 2025 | |||
| GOLDMAN SACHS GROUP INC | 2% | -77% | $2,546,902 | -$6,958,784 | 2,274,020 | -73% | THE GOLDMAN SACHS GROUP, INC. | 30 Jun 2025 |
| Schonfeld Strategic Advisors LLC | 0.82% | -85% | $1,050,024 | -$7,679,831 | 937,521 | -88% | Schonfeld Strategic Advisors LLC | 30 Jun 2025 |
As of 31 Mar 2026, 154 institutional investors reported holding 74,091,253 shares of FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share (FATE). This represents 61% of the company’s total 122,342,805 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
54%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Redmile Group, LLC | 11% | 12,872,946 | 0% | 1% | $15,447,535 |
| BlackRock, Inc. | 8.2% | 10,068,614 | -1.1% | 0% | $12,082,337 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.4% | 4,192,063 | 0% | 0% | $5,030,476 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 3.4% | 4,134,585 | 0% | 0% | $4,961,502 |
| ACADIAN ASSET MANAGEMENT LLC | 3.4% | 4,120,200 | +41% | 0.01% | $4,938,000 |
| TWO SIGMA INVESTMENTS, LP | 2.8% | 3,466,786 | +100% | 0% | $4,160,143 |
| JOHNSON & JOHNSON | 2.8% | 3,379,064 | 0% | 0.62% | $4,054,877 |
| AQR CAPITAL MANAGEMENT LLC | 2.5% | 3,001,521 | +158% | 0% | $3,601,825 |
| RENAISSANCE TECHNOLOGIES LLC | 2.4% | 2,974,683 | +26% | 0.01% | $3,569,620 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.1% | 2,590,429 | +4.9% | 0% | $3,109,189 |
| STATE STREET CORP | 1.8% | 2,263,173 | -0.09% | 0% | $2,715,808 |
| UBS Group AG | 1.5% | 1,821,715 | +351% | 0% | $2,186,058 |
| GOLDMAN SACHS GROUP INC | 1.1% | 1,327,757 | -7.5% | 0% | $1,593,309 |
| TANG CAPITAL MANAGEMENT LLC | 0.95% | 1,167,773 | 0% | 0.07% | $1,401,328 |
| CITADEL ADVISORS LLC | 0.77% | 942,926 | +26% | 0% | $1,131,511 |
| DIMENSIONAL FUND ADVISORS LP | 0.72% | 883,790 | -44% | 0% | $1,060,068 |
| Irenic Capital Management LP | 0.72% | 878,055 | 0.1% | $1,053,666 | |
| NORTHERN TRUST CORP | 0.66% | 811,920 | +11% | 0% | $974,305 |
| Monaco Asset Management SAM | 0.66% | 810,000 | -2.4% | 0.31% | $972,000 |
| Bruce & Co., Inc. | 0.65% | 789,188 | +8.2% | 0.27% | $947,026 |
| MORGAN STANLEY | 0.63% | 767,748 | -16% | 0% | $921,298 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.62% | 756,273 | -3.6% | 0% | $907,528 |
| VANGUARD FIDUCIARY TRUST CO | 0.53% | 653,761 | 0% | 0% | $784,513 |
| JANE STREET GROUP, LLC | 0.53% | 646,979 | -23% | 0% | $776,375 |
| DAFNA Capital Management LLC | 0.45% | 550,000 | 0% | 0.15% | $660,000 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
49
Latest
Q1 2026
Rows shown
1-25 of 49
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 74,091,253 | $88,865,631 | +$3,266,686 | $1.20 | 154 |
| 2025 Q4 | 72,135,207 | $70,931,982 | -$11,120,163 | $0.98 | 145 |
| 2025 Q3 | 80,446,666 | $101,355,707 | +$1,878,808 | $1.26 | 138 |
| 2025 Q2 | 79,555,724 | $88,833,451 | -$17,593,195 | $1.12 | 136 |
| 2025 Q1 | 96,451,503 | $76,210,377 | -$16,246,755 | $0.79 | 127 |
| 2024 Q4 | 100,742,490 | $166,216,764 | -$49,322,737 | $1.65 | 154 |
| 2024 Q3 | 114,626,757 | $401,134,107 | -$26,268,311 | $3.50 | 157 |
| 2024 Q2 | 122,159,363 | $400,671,566 | -$37,762,295 | $3.28 | 176 |
| 2024 Q1 | 122,980,750 | $902,678,660 | +$225,457,297 | $7.34 | 160 |
| 2023 Q4 | 95,368,059 | $356,677,597 | -$5,241,221 | $3.74 | 152 |
| 2023 Q3 | 95,698,313 | $202,876,531 | -$41,469,527 | $2.12 | 164 |
| 2023 Q2 | 109,140,532 | $519,540,682 | -$18,388,551 | $4.76 | 183 |
| 2023 Q1 | 112,556,300 | $641,545,712 | -$48,046,056 | $5.70 | 177 |
| 2022 Q4 | 105,538,752 | $1,064,884,147 | -$72,227,908 | $10.09 | 222 |
| 2022 Q3 | 107,847,419 | $2,414,270,747 | -$51,535,763 | $22.41 | 226 |
| 2022 Q2 | 109,105,314 | $2,682,160,938 | +$198,082,382 | $24.78 | 212 |
| 2022 Q1 | 101,146,307 | $3,918,572,903 | +$154,288,770 | $38.77 | 235 |
| 2021 Q4 | 96,474,919 | $5,644,897,783 | +$10,118,846 | $58.51 | 240 |
| 2021 Q3 | 95,702,027 | $5,670,584,893 | +$32,917,992 | $59.27 | 254 |
| 2021 Q2 | 94,438,853 | $8,194,463,579 | +$63,508,082 | $86.79 | 264 |
| 2021 Q1 | 93,763,343 | $7,731,987,612 | +$546,947,235 | $82.45 | 251 |
| 2020 Q4 | 87,411,381 | $7,948,482,716 | -$84,784,180 | $90.93 | 247 |
| 2020 Q3 | 87,813,890 | $3,509,314,003 | +$84,938,020 | $39.97 | 210 |
| 2020 Q2 | 85,944,579 | $2,946,905,994 | +$357,311,792 | $34.31 | 199 |
| 2020 Q1 | 75,606,763 | $1,679,422,294 | +$78,833,879 | $22.21 | 153 |